Article
The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway.
Cellular & molecular immunology - 1 Nov 2020
Deng Rilin, Zuo Chaohui, Li Yongqi, Xue Binbin, Xun Zhen, Guo Yanxia, Wang Xiaohong, Xu Yan, Tian Renyun, Chen Shengwen, Liu Qian, Chen Jinwen, Wang Jingjing, Huang Xiang, Li Huiyi, Guo Mengmeng, Wang Xintao, Yang Miaomiao, Wu Zhihui, Wang Jinfeng, Ma Jiahuan, Hu Jun, Li Guangdi, Tang Songqing, Tu Zhengkun, Ji Hongbin, Zhu Haizhen
Abstract excerpt
The ability to harness innate immunity is a promising solution for improving cancer immunotherapy. Interferon (IFN) induces expression of IFN-stimulated genes (ISGs) by activating the JAK-STAT signaling pathway to promote innate immunity and inhibit malignant tumor growth, but the functions and mechanisms of most ISGs in cancer regulation are unknown. As an innate immune effector, ISG12a promotes the innate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.